Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Standing in Success with Evan Reddick, AVP and Head of Global Medical Affairs Strategy at Menarini Stemline

Dec 21, 202228 minAudio

Evan Reddick recently joined an exciting emerging biotech with a major phase 3 trial win, and preparing to launch a first-in-class oral medication for breast cancer, serving as the AVP and Head of Global Medical Affairs Strategy. Evan previously had a number of field and leadership roles at a large pharma. A highlight was the very first topic discussed, the framework of “Standing in Success”, and what that means for leaders. But we covered so much, I'm really excited to hear what you ha... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_01Hello and welcome to Pharma Sessions, where medical affairs people hear from each other and maybe learn a little something. We covered so much in this episode, I want to get right to it. Evan Reddick recently joined an exciting emerging biotech with a major phase three trial win. He's preparing to launch a first in-class oral medication for breast cancer. He's serving as the AVPN head of global medical affairs strategy, having previously had a number of field and leadership roles at Large Pharma. A highlight for me was the very first topic we discussed: the framework of standing in success and what that means for leaders.

SPEAKER_01But there are so many gems, I don't want to delay further. So let's dive in. As always, the views expressed here are our own and don't reflect those of our respective employers. Good morning, Evan. How are you today? Good morning, John. I'm well. Thank you for having me. Very pleased to have you here. As we were prepping for this call, you started talking a little bit about this model of standing and success. And I'm hoping you could just share a little bit more about what that means and particularly from a Metafairs standpoint.

SPEAKER_00Yeah, I'd I'd be happy to. And you know, as I shared with you previously when we were when we were talking about this podcast, uh, one, I'm very excited to do this. I've I've watched your other podcasts, and I think it's a really useful tool to get you know interesting new thoughts out to folks who who will consume them and then use them uh in in their daily lives, use them in their professional careers, et cetera.

SPEAKER_01Yeah, I mean that is honestly that's the goal. The perfect outcome here is that we get to something that's interesting enough or useful enough that somebody takes out a pen and jots it down. So that's what we're trying to uncover, and hopefully we'll get there today.

SPEAKER_00All right, awesome. Well, I hope that we can I hope we can do that. Um so thanks for the question. This is something that you know you and you and I were chatting about previously about standing in success. And I can't take credit for creating that that that language there. Uh, I'm sure I picked it up or I heard it somewhere, but this is something that I feel that as you're developing, um, as you want to develop and implement strategies to get you to a place, it it's far easier to go and just magically move yourself to that place. So let's say that uh you're creating a three to five year snapshot in the future of where you want to take your um your drug.

SPEAKER_00If you're with a pharma company or you want to take your widget, if you're with a widget manufacturing company, but you want to take your product and your your goal to a certain place. So logically, we've just leaped from one side of the chasm to the next, and we've magically appeared in success. And it's three years from now, and our product has been launched on the market and it's being uptaken, and we've got 80% market share, and we're very pleased with that. Fantastic, but that's complete fantasy. The question, of course, now we're standing in success.

SPEAKER_01Right.

SPEAKER_00The question now is how did we get there? And we've we we look behind us, and I'm reminded of like Indiana Jones and Radio Raiders of the Lost Ark, where you know he has to go across this rickety rope bridge. And to me, there's no bridge right now, and what holds up a bridge is pillars. And so as we think backwards of how we got to this landscape, this successful outcome, we need to work backwards and say, all right, I need, I don't know, three, four, maybe five very strong strategic outcomes that we've we've generated that we've worked toward and generated.

SPEAKER_00And those are our large pillars that hold up this massive bridge that's going to carry us from our current position over into the success three years from now. So those giant pillars are, you can look at those as strategic imperatives that belie your uh your your scientific narrative for a pharma product. Those strategic pillars then are connected by little rope bridges. And those those little those little bridges, all those little walking paths, those are the individual tactics that have to be implemented in order to allow a team to go from one strategy, one successful implementation to the next.

SPEAKER_00Uh taken together, I think that's how you get across the chasm of you know competitive pharma business.

SPEAKER_01Well, I love that because you know medical affairs is so specialized, but what you're talking about isn't actually a super specialized approach, right? It's actually when I when I was in business school, one of the very first exercises that we did was the scenario where it was a team scenario, your team has been in an uh airplane crash and is trapped in like the Canadian tundra, and you have a certain set of materials and you need to figure out how you're gonna solve the problem.

SPEAKER_01And there is a right answer based on you know what survival experts say and all of that. But the point of it was the very first thing you need to do is figure out are you gonna try to be rescued or are you gonna go try to make a trek across, right? So you're you're creating that vision of what does success look like, and then everything else, all your other decisions flow through to that. So that's sort of like a universal leadership technique or creating a shared vision. Um, and I'm I'm curious, one of the things to bring it specifically to medical affairs that I like about this is like the pillars and the tactics.

SPEAKER_01A lot of times Metafairs leaders still struggle to sort of quantify what the value of it, of their work is or what they're bringing to the organization, but you're creating a roadmap, right? And so I'm just curious, as you're having these conversations with your management, are you uh are you aligning metrics to these sort of pillars and and tactics? Does that sort of go into addressing that that problem? How does that work?

SPEAKER_00So you you've brought up the uh uh a very challenging uh three-letter word, KPIs. KPIs. So I think all of us who've been in pharma for a while uh both love and hate KPIs. Being able to quantify something that's that's essentially qualitative is challenging. And in order to implement the appropriate KPIs and not have you know your head in the clouds and not be unrealistic and set strange and unrealistic expectations, is that we have to understand what are the absolute critical success factors that underlie each one of your, let's say, strategic imperatives.

SPEAKER_00The strategic imperatives or the the pillars, the strategic pillars that we've just discussed, those are very difficult, difficult to quantify. Those are exceptionally easy to qualify. And say that, let's say I want to get um 50% of clinicians in the United States to be aware of an upcoming molecule from um a smaller company. That my goal is 50. Let's just be realistic, right? Um, that that is a strategy, and that can be measured by you know working with a vendor and polling clinicians and asking them, do you know of this company?

SPEAKER_00Do you know of this molecule? And do you understand what the molecule is going to treat? So that's a pretty straightforward one. However, I would actually back up and say that the tactics themselves are probably easier and and easier to quantify. And where the tactics I think come in is this is the the coordination of I I have to, I'm a former MSL myself. I started my career as an MSL in pharma. Um, the role of the MSL and quantifying how many clinicians they they reach out to.

SPEAKER_00Taking those quantifiable interactions, turning them into actionable insights that are then able to be looked at as insight, implication, and action. Those those tactics roll together to become their own strategic focus for the field team. But again, we can say we want 50% knowledge of our of our product at the end of six months, right? We're gonna make it a um uh a measurable, time-dependent, and realistic goal.

SPEAKER_00But we can break that down and say, all right, we need field teams now reaching out and having conversations with 25 academic clinicians and a hundred um uh community clinicians every quarter. Yep. And this this this sort of uh this game plan of saturation is what what needs to be done, and that is exceptionally well quantifiable. However, of course, you're now asking your your MSLs to go out there and count the clinicians they talk to and not necessarily the the uh the impact of the insights.

SPEAKER_00And there's a there's a fine balance there, I think, that we could have a whole different discussion on. Sure. Yeah.

SPEAKER_01So so when you're doing this, and I think it to me this makes a lot of sense, right? Where you're starting with the you're starting with the end in mind and then working backwards and your pillars and your tactics roll through. And it's implicit that if you do the tactics that we've your whole organization has agreed upon, will support the pillars and will drive the strategy, then you'll see success. My question is, how do you how have you found it's been getting alignment on all of those elements, like the the what success looks like and and going on through?

SPEAKER_01And has that been different in big pharma versus small pharma?

SPEAKER_00Yeah, great question. Um, you know, I I mentioned previously I started my career as an MSL. I did so in a top five pharma company, uh, 80,000 employees globally, very large organization, very wide triangle of leadership, as you can imagine. Um in a large organization, communication is done so by the by the leads of all the different functional roles. So the regional director would have communication back and forth with the national liaison lead, who would then talk to the vice president, who would get their you know, their overarching strategic value, uh strategic imperatives and aims from the senior vice president who essentially rolls up into the CMO.

SPEAKER_00And that sort of that that smooth, I'll say, smooth coordination there uh is done in a large company because you have you you have information flowing largely in one direction. In a small company, and I hate to use these uh the these these industry tropes, but in a small company, you truly are building a plane while you fly it. Um I am uh I I I think I'm employee 300 and something at uh at a relatively small biotech that's owned by a much larger parent organization, but this biotech is allowed to operate relatively independently as an oncology um in an oncology expertise area.

SPEAKER_00And so I found that in a smaller company the communication not just is, but absolutely must be two-way and must span the entire gamut from CEO down to field medical employee. This this level of communication sounds like chaos, and I think to the untrained eye, it actually is. But um, much like early cavemen you know spoke in paintings on a wall, we speak through PowerPoint.

SPEAKER_00And so I will develop slides that vary as clear as I can be, clearly lay out here's where we want to be. Again, standing in the result, this is this is what I would like to implement in six months. And then I'll take a my next slide will be here's where we are today. And in order to implement this, I feel that these, let's say, these these three key components need to be created, implemented, uh, created, agreed upon, and then implemented. And this is where you have key stakeholder engagement.

SPEAKER_00At a small company like mine, like like the one I'm at now, um titles matter far less. Right. And it's about influence without authority. And so I I may not have the field team, for example, in this in my in my new role, field team does not report up into me. However, I need the field team to do things in order to achieve the goals that we've all set collaboratively. And so this influence without authority comes from uh very clear communication, building rock steady trust, and then executing on what you said you'd do.

SPEAKER_00And it's just rinse-repeat after that. Um, but if you if you're not if if you're if you're not doing anything, you need to be communicating. That's the key role because I I was told this by my regional director when I was a field employee um eight years ago. Um, surprises in pharma are bad. Now that might seem logical, right? The surprises are bad, and I would agree, bad surprises are always bad, right? Um however, good surprises are equally bad. And this took me a little while to sort of wrap my head around.

SPEAKER_00Um, when people have communicated, when people have created these strategic imperatives, when people have created tactics that all ladder up to an end result, even a good surprise changes the logical flow of what we had planned. And it requires that people come together in a group and address that issue. There will always be surprises, but we can limit the number of surprises that we have internally, for example, by controlling our environment as best as we can and then being able to react to out outside pressures.

SPEAKER_01It's so interesting because you're talking talking about some things that oftentimes farm companies do a lot of of like talking to key stakeholders outside their organization, right? Gathering insights and making plans from this, but what you're referring to is stakeholders inside the organization and getting getting their buy-in. Um I'm just curious, having experienced both more of the top-down and then that collaborative approach, do you get a sense that people feel more of a sense of ownership from from from it from being part of that?

SPEAKER_01Or is it something where actually the top-down seems to seem to work fine, right? Is that something that people should care about or or not, in your opinion? This episode is sponsored by Structured Meetings. It's a Teams app that turns your own Teams incidents into the perfect advisory board platform. Save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com.

SPEAKER_00I'm biased because it's been my experience and I'll share my experience, but but I I think that there are there's folks that sit on both camps. I I I'd really, you know, there are some folks who are absolutely thrilled to be in one role with one title their entire career. And and I my hats off to them because they know what they want, that they're happy with it, and they're able to do it with excellence. And after you get really good at that role, it you don't have to try as hard anymore. And you you every year you make a little bit more salary and they're happy.

SPEAKER_00And I'm we need we need roles and we need folks like that. And then you have folks who who would like to climb the corporate ladder, who would like to gain more leadership opportunities. Um, I will share that that um as I was developing as an MSL, I felt more empowered when it was shared with me what the results of my work did. And for a long time, uh again, as a field employee myself, for a long time, you know, headquarters was a black box. I I wasn't really sure where my insights went.

SPEAKER_00I I diligently put them into Viva and I or I thought about them and I'm I'm thinking about the core strategies that I'm aware of. I'm thinking about the tactics that I'm implementing in my territory in order to achieve these larger strategic pillars. And I'm inputting what I believe to be actionable insights. However, oftentimes we don't know where those insights go. And it wasn't until um some of that got got demystified that I started realizing, ah, so this is how my my insights get used.

SPEAKER_00And I would encourage anybody listening to this that that doesn't understand where their insights are, ask. Have the conversation with your manager, have the conversation with when you do have your skip level meetings with your manager's manager, ask the question where you know, how how have my efforts, how have the efforts of my team uh changed the direction of business? Um because I I firmly believe that there are there are two types of outcomes uh in in in pharma. There is an outcome that that's brought about and ultimately changes the direction the company takes strategically.

SPEAKER_00And I uh as a uh the head of strategy for a small company, I absolutely am thrilled by those. We see a set of insights coming in over time that highlight a trend, and now we now we now know that there's been a shift and we can alter our strategy in order to address that. That's phenomenal. That changes the way your company works. Um, the other type, of course, is an external uh is an external change where your efforts and your insights reveal um a change in business that you're able to communicate externally and cause a change in behavior.

SPEAKER_00This is much, much more difficult, but it is sort of the holy grail of pharma and medafairs is can we change prescribing habits through the concerted efforts of evidence and confidence that ladder up to make a clinician come to the realization that wow, maybe I should use that molecule in this setting. Yep. And so that that's really the key there. So I so through communication and through sort of demystifying the process, it it empowers folks to understand their role better and ultimately do their job better.

SPEAKER_00And I I find that that, at least in small pharma where I am now, um there's so much more communication. And as I mentioned, in you know, in large pharma, you have that very, very wide and tall triangle of hierarchy. And it's oftentimes difficult to get time on folks' calendars. Um, I will tell you, there are, you know, we have meetings between SVPs and MSLs all the time at small companies because again, titles don't matter as much, and just getting the job done does.

SPEAKER_01Well, and I think part of the communication is oftentimes like somehow having a single point of truth, right? And that is evolving over time as you're gathering, hearing these insights or external changes are happening. Can you talk at all about what points of truth you have, whether it's scientific narrative or value prompts or how those play together and how that works to kind of help create alignment across all of the different different roles?

SPEAKER_00Yeah, um that's an exceptionally broad question. A really good one is one that we have to struggle with consistently, day in and day out. Um, I I think you know there's some key points of truth that we try to implement, and that really all ladders together into one uh one slide. Again, the whole you know, cavemen painting on walls or uh, you know, uh pharma executives communicating through uh through PowerPoint. But one thing that I think is absolutely critical is for teams to come together and create a coherent sort of start-to-finish scientific narrative.

SPEAKER_00How do we how do we view our molecule? How do we believe it's gonna change the the current landscape once it comes to market or or in market? How do we want to be utilized? And what change do we want to bring about? Do we want to bring about ease of use for clinicians? Do we want to bring about better diagnostic analysis to highlight better patient populations? And and ultimately, you know, what is the quantifiable metric by which we want to change patients' lives?

SPEAKER_00Are we trying to give them an additional three or four months? Are we trying to give them three or four years? Are we trying to cure their disease? So these are the sort of areas that we we think about that we're we're bugged at 2 a.m., waking up and we think about is how can we clearly identify the absolute must-wins for our our molecule for our for our current remit. And then once we've generated that those multiple points of truth, those ladder together again, much like that that bridge we've built across the chasm to take us into success, um, those those moments of truth, those points of truth ladder together into a coherent and very articulable scientific narrative.

SPEAKER_00That we then need to again communicate. Communication is such a key thing, is we communicate that very clearly across globally to all of our field, all of our teams, whether they be field or headquarters, such that uh, and then of course I should back up, and then at a certain level, um at least where I am currently, we have to uh cross-populate that across to clinical development, early development, marketing, and then commercial, both sales and non-sales, right? Um, compliantly, of course, within that separation of uh commercial and medical.

SPEAKER_00But once that has been completed and the entire organization understands the moments of truth, the points of truth, the full scientific narrative, now it's now it's time to take that externally and begin communicating externally because now we're all marching in lockstep, we're all using the same acronyms, we're all using the same terminology, and we all have a very clear goal in mind, and that that vision has now sort of come. You it it goes from being that ethereal, you know, gaseous, difficult to grab and and think about, and it turns into you know a marble sculpture, and it's very solid, and you know exactly what it looks like.

SPEAKER_00Now you can go out and communicate and talk about it.

SPEAKER_01Yeah, and the internal cross-pollination is always so interesting to me because it all has to, it all just has to work well together, right? Commercial needs to be aligned to medical, and access needs to be having the pro communicating properly to either payers or national healthcare systems or whoever they happen to be uh responsible for um in order for it to work, in order for people to get access to to the drugs. And I think that it's building a scientific narrative that is sort of relying on that virtuous circle of of getting the insights as they come in and keeping it as.

SPEAKER_01As a living document, but then, as you said, ladders up to this very clear value statement of what it is that your drug is going to deliver. That process in and of itself is kind of fascinating to me because I feel like if it's done right, then you're kind of giving each person, regardless of the conversation, he or she is going to have the tool that they need to have that, have that conversation with data and with um sort of person, not personalized, but like uh the ability to customize the value prop for their particular conversation.

SPEAKER_00It it allows for custom tailoring where necessary.

SPEAKER_01Yeah.

SPEAKER_00But we all have agreed on which fabrics to use, et cetera, to use the tailoring metaphor. I I'll I'll share with you that um so my wife and I have been married for for 15 years. My wife and I met through a mutual love of cooking. And so when we've moved from house to house and and and when I've moved from roll to roll, this required a move, uh, we've either searched out for a house that has an amazing kitchen, or in the case of my most recent uh move, uh we we had the the good luck of being able to build a home and we joke that we built a house around a kitchen.

SPEAKER_00Um we just we love cooking. And so to me, proper execution in in global medical affairs that rolls out to the countries, then ultimately rolls into the regions and then rolls down to the field level, proper execution in medical affairs is is a is a well-made recipe that yes, a few, a few people were involved in the creation of that recipe, using the insights that came back from everyone else, of course. But like I think a few people are involved in creating that message and that narrative.

SPEAKER_00That message and narrative is then sent out across the cross-functional teams, and then ultimately being able to step back and allow any chef to come in the kitchen. And as long as they follow that recipe, yeah, it might have a different flavor, it might have a different flair, it might have a couple extra ingredients depending on um you know which kitchen it's being cooked in. But as long as everyone is following that same general guidance, that same recipe, you can with with almost certainty, you can feel confident that its execution is going to ladder up to and and get people across that that bridge that we've built over into that land of success.

SPEAKER_01I love that metaphor. And actually, that to me seems like a very nice place to to end our end our discussion. So um thank you so much. This was this was really fun and informative, and I feel like we got covered all covered a lot in a short time, which is the perfect result, I think.

SPEAKER_00Wonderful. I'm I'm really happy to be here, and I'll I'll just reiterate really quickly that um I've had a successful career so far because of exceptional managers and because of exceptional communication and knowing what's needed, when it's needed, and how much is needed. And if you don't know, if you're listening to this podcast and you want some really high specifics, I think that that's the question you need to ask yourself is do you understand what you're being asked to do? And if the answer is anything except for a yes, you need to communicate more, have ask more questions.

SPEAKER_00Um, and and that that's really I think the key to success is knowing exactly what is needed. Um, I will also share just briefly, because I need to say this out loud, is that my opinions are of are mine and mine alone and don't represent um the organization uh for which I work. So just being clear here and and um indemnifying myself like a good a good medical affairs employee. Excellent. Evan, thank you so much. Have a wonderful day. Send to you, John.

SPEAKER_01This episode is sponsored by Structured Meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in Teams? And the answer back then was not really. Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own Teams instance.

SPEAKER_01It changes teams just enough to check all the boxes for what's needed for great ad boards. And also, it's super fast and it saves people a ton of money. Visit www.structured meetings dot com for more info. All right, back to the show.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode